Scarica l'app Stockscreener
4.96
0.61%
0.03
Dopo l'orario di chiusura:
4.96
Galecto Inc Borsa (GLTO) Ultime notizie
Sunshine Biopharma (NASDAQ:SBFM) Stock Quotes, Forecast and News Summary - Benzinga
Critical Analysis: Galecto (NASDAQ:GLTO) vs. ObsEva (NASDAQ:OBSV) - Defense World
(GLTO) On The My Stocks Page - Stock Traders Daily
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Analyzing Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
Where are the Opportunities in (GLTO) - Stock Traders Daily
Galecto CEO Hans T. Schambye sells $7,509 in shares - Investing.com
Galecto (NASDAQ:GLTO) Shares Up 22.6% – Should You Buy? - Defense World
When (GLTO) Moves Investors should Listen - Stock Traders Daily
Galecto stock plunges to 52-week low at $4.78 amid market challenges - Investing.com Australia
Galecto stock hits 52-week low at $5.26 amid market challenges - Investing.com Nigeria
Galecto stock hits 52-week low at $5.26 amid market challenges By Investing.com - Investing.com South Africa
(GLTO) Trading Signals - Stock Traders Daily
Galecto stock hits 52-week low at $5.51 amid market challenges - Investing.com Australia
GLTO (Galecto) Momentum Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
Idiopathic Pulmonary Fibrosis Market Report 2034, - openPR
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
GLTO (Galecto) EBITDA per Share : $-17.96 (TTM As of Sep. 2024) - GuruFocus.com
Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell? - Defense World
Galecto stock hits 52-week low at $6.46 amid market challenges - Investing.com India
Galecto Inc. (GLTO) Quarterly 10-Q Report - Quartzy
(GLTO) Investment Report - Stock Traders Daily
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities - MSN
Galecto reports Q3 EPS ($3.39) vs ($7.50) - MSN
Galecto, Inc. Announces Strategic Shift and Financial Overview - MSN
Galecto Reports Third Quarter 2024 Financial Results - The Manila Times
Global Secondary Myelofibrosis Therapeutics Market Poised to Reach USD 2.74 Million by 2033 with a 6 - PharmiWeb.com
Galecto price target raised to $10 from $9 at Oppenheimer - Yahoo Finance
How to Take Advantage of moves in (GLTO) - Stock Traders Daily
Galecto (NASDAQ:GLTO) Price Target Increased to $10.00 by Analysts at Oppenheimer - MarketBeat
Galecto (NASDAQ:GLTO) Given New $10.00 Price Target at Oppenheimer - MarketBeat
Galecto adds Dr. Amy Wechsler to Board of Directors By Investing.com - Investing.com Canada
Galecto stock hits 52-week low at $6.61 amid market challenges - Investing.com Canada
Galecto adds Dr. Amy Wechsler to Board of Directors - Investing.com
Galecto Appoints Dr. Amy Wechsler to Board - TipRanks
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - The Manila Times
Galecto refocuses on cancer, acquires novel AML drug rights By Investing.com - Investing.com South Africa
Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail
Galecto stock hits 52-week low at $9.3 amid market challenges - Investing.com
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):